Have you been diagnosed with urothelial carcinoma? If so, you may be able to take part in a research study evaluation of an investigational treatment called FX-909 in cancer patients.

Have you been diagnosed with Liver cancer. If so, you may be able to take part in a research study looking to to measure the efficacy and safety of durvalumab IV solution plus bevacizumab IV solution after transarterial radioembolization(Y90 glass microsphere TARE) in participants with unresectable HCC amenable to locoregional therapy

The purpose of this study is to evaluate an investigational ultrasound technique called acoustic angiography to improve physicians' ability to assess cancer risk.

Do you have advanced or metastatic non small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal cancer, or renal cell carcionma? Have you tried previous therapies that did not work? If so, you may be able to take part in this study. Investigational study drug is provided.

This study aims to find better ways to serve children with autism spectrum disorder (ASD). We will use 3 rounds of online surveys to develop a list of functionality features that are most relevant for serving school-age autistic children. We hope this list can be used to improve services and support for those who are on the autism spectrum.

This is a study for people with early-stage inoperable lung cancer. We want to find out if adding a drug called atezolizumab to stereotactic body radiation therapy (SBRT) is more effective than SBRT alone for this type of cancer.

Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.